Novartis, a Swiss drug manufacturing company, has expressed satisfaction with its LCZ696 chronic heart disease treatment drug. This drug has shown dramatic effectiveness in treating heart disease patients that have ejection fraction or HF-REF, and it has proven to work for patients with failing hearts.
The LCZ696 is taken twice a day, and it is a tablet that is found superior to the ACE-inhibitor enalapril which was usually administered to heart attack patients. The new Novartis LCZ696 drug dramatically reduces the likelihood of urgent hospitalizations for patients with heart conditions by 21%, and it has been found to reduce the possibility of death in heart patients by 16%, while also reducing cardiovascular-related deaths by 20%.
The LCZ696 is taken twice a day, and it is a tablet that is found superior to the ACE-inhibitor enalapril which was usually administered to heart attack patients. The new Novartis LCZ696 drug dramatically reduces the likelihood of urgent hospitalizations for patients with heart conditions by 21%, and it has been found to reduce the possibility of death in heart patients by 16%, while also reducing cardiovascular-related deaths by 20%.
David Epstein, the Novartis division head states that “we want to thank leading cardiologists from around the world for their collaboration with us and their determination in advancing this important new life-saving therapy for heart failure patients.” Currently, Novartis is seeking approval from the Food and Drug Administration agency of the US to market the drug in the United States, and they also seek marketing authorization to make the drug available within the European Union early next year.
The LCZ696 works by suppressing the harmful system (RAAS) and then improving the protective neurohormonal capabilities of the heart (NP system). Its effectiveness has been found constant and sustained across all clinical subgroups trials, and it is looked upon as the new life-saving drug for patients with chronic and threatening heart conditions.
